We are an independent, global, inter-disciplinary, non-partisan group of policy-makers, scholars, scientists, strategists and others convened to think through the wide range of issues and crises associated with the Covid-19 pandemic. The Commission’s purpose is to enable informed discourse and decision-making, to frame priorities and help build consensus on policy solutions to strengthen societal and global resilience. The full list of Commissioners can be found here.


By Bill Emmott and Berel Rodal, co-directors, GCPPP, November 28th 2021

The Global Commission’s assessment of the state of the world amid what needs to be treated by policy-makers as “the perpetual pandemic”, and considered as part of four mutually reinforcing crises, of health/biology, ecology/climate, trust/legitimacy and geopolitics/international order.

Leading Indicators: January vaccine output

Pfizer/BioNTech has leapfrogged into the lead as the world’s biggest COVID-19 vaccine producer, both for the month of January and for total output since the vaccine rollout began. January saw a virtual shutdown in the two Chinese giants’ output, helping more than halve the global monthly total from 1.58 billion doses in December to 729.6 million in January. Nonetheless, India has maintained its position as the third largest location of production as Bharat’s vaccine joined AstraZeneca’s in major production volumes. The global total of vaccine doses so far produced has reached 11.7 billion.

Unvaccinated Africa and the perpetual pandemic


By Bill Emmott, co-director GCPPP, February 17th 2022

Given the still snail-like progress of vaccinations in sub-Saharan Africa, it is virtually certain that more Covid-19 variants will emerge, keeping this pandemic going

What we know about Omicron

By Dylan Barry, GCPPP Staff, February 1st 2022

In this ANALYSIS, we summarise the best available evidence on the Omicron variant. The issues we explore:

  1. What do Omicron’s origins tell us about the prospects of future variants?
  2. To what extent does Omicron evade pre-existing immunity and how good have existing vaccines proved to be against it?
  3. How transmissible is Omicron?
  4. How severe is Omicron?
  5. Why do countries’ experiences with Omicron seem so varied?